[go: up one dir, main page]

AU2001295017A1 - Solid dose nanoparticulate compositions - Google Patents

Solid dose nanoparticulate compositions

Info

Publication number
AU2001295017A1
AU2001295017A1 AU2001295017A AU9501701A AU2001295017A1 AU 2001295017 A1 AU2001295017 A1 AU 2001295017A1 AU 2001295017 A AU2001295017 A AU 2001295017A AU 9501701 A AU9501701 A AU 9501701A AU 2001295017 A1 AU2001295017 A1 AU 2001295017A1
Authority
AU
Australia
Prior art keywords
solid dose
compositions
nanoparticulate compositions
dose nanoparticulate
nanoparticulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295017A
Inventor
Stephen B Ruddy
Niels P. Ryde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24674479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001295017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of AU2001295017A1 publication Critical patent/AU2001295017A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.
AU2001295017A 2000-09-21 2001-09-04 Solid dose nanoparticulate compositions Abandoned AU2001295017A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/666,539 US6375986B1 (en) 2000-09-21 2000-09-21 Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US09666539 2000-09-21
PCT/US2001/041976 WO2002024163A1 (en) 2000-09-21 2001-09-04 Solid dose nanoparticulate compositions

Publications (1)

Publication Number Publication Date
AU2001295017A1 true AU2001295017A1 (en) 2002-04-02

Family

ID=24674479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295017A Abandoned AU2001295017A1 (en) 2000-09-21 2001-09-04 Solid dose nanoparticulate compositions

Country Status (12)

Country Link
US (2) US6375986B1 (en)
EP (1) EP1318788B1 (en)
JP (1) JP4460827B2 (en)
AT (1) ATE381317T1 (en)
AU (1) AU2001295017A1 (en)
CA (1) CA2416109C (en)
CY (1) CY1107305T1 (en)
DE (1) DE60131991T2 (en)
DK (1) DK1318788T3 (en)
ES (1) ES2298270T3 (en)
PT (1) PT1318788E (en)
WO (1) WO2002024163A1 (en)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
JP2002525311A (en) * 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド Sustained release nanoparticle composition
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
RU2236847C2 (en) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Composition as multiple particles with modified release
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
KR20010073232A (en) * 1998-11-20 2001-07-31 추후제출 Dispersible Phospholipid Stabilized Microparticles
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
JP4464129B2 (en) * 2001-09-19 2010-05-19 エラン ファーマ インターナショナル，リミティド Nanoparticulate insulin preparation
BR0212833A (en) * 2001-09-26 2004-10-13 Baxter Int Preparation of submicron sized nanoparticles by dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
UA76810C2 (en) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Pharmaceutical compositions of tachikinine receptor antagonist in form of nanoparticles
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DK1471887T3 (en) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanoparticle compositions having lysozyme as a surface stabilizer
EP1498116A1 (en) * 2002-03-20 2005-01-19 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1490025B1 (en) * 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
EP1800666A1 (en) * 2002-03-20 2007-06-27 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
EP2263650A3 (en) 2002-04-12 2013-12-25 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (en) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド Nanoparticulate policosanol formulations and novel policosanol combinations
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
DK1553927T3 (en) * 2002-09-11 2011-01-31 Elan Pharma Int Ltd Gel-stabilized, nanoparticle active ingredient compositions
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US7090859B2 (en) * 2002-12-13 2006-08-15 Ronald Thomas Haas Ketoprofen compositions and methods of making them
US20040173696A1 (en) * 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
JP4469846B2 (en) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド Nanoparticulate topiramate formulation
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US20100297252A1 (en) * 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
MXPA05012632A (en) * 2003-05-20 2006-02-22 Ranbaxy Lab Ltd Pharmaceutical compositions of acitretin.
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
ATE509618T1 (en) * 2003-11-05 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE-SHAPED COMPOSITIONS HAVING A PEPTIDE AS A SURFACE STABILIZER
KR100603974B1 (en) 2003-12-05 2006-07-25 김갑식 Method for preparing nano-scale or amorphous particle using solid fat as a solvent
WO2005060610A2 (en) * 2003-12-11 2005-07-07 The Trustees Of Columbia University In The City Ofnew York Nano-sized particles, processes of making, compositions and uses thereof
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
US8535716B2 (en) * 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
WO2006083326A2 (en) * 2004-08-07 2006-08-10 Cabot Corporation Gas dispersion manufacture of nanoparticulates and nanoparticulate-containing products and processing thereof
US20060083694A1 (en) 2004-08-07 2006-04-20 Cabot Corporation Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
EP1827374B1 (en) * 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (en) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
US20080145430A1 (en) * 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
AU2005316473B2 (en) * 2004-12-15 2011-07-14 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
JP2008526855A (en) * 2005-01-06 2008-07-24 エラン ファーマ インターナショナル リミテッド Nanoparticulate candesartan formulation
EP2332524A1 (en) 2005-02-15 2011-06-15 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
EP1863450A1 (en) * 2005-03-16 2007-12-12 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
CA2601312A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
KR20070121786A (en) 2005-03-23 2007-12-27 엘란 파마 인터내셔널 리미티드 Nanoparticulate Corticosteroids and Antihistamines
US20060229585A1 (en) * 2005-04-11 2006-10-12 Minu, L.L.C. Drug delivery to the crystalline lens and other ocular structures
US7722581B2 (en) * 2005-04-11 2010-05-25 Gholam A. Peyman Crystalline lens drug delivery
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
MX2007012762A (en) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising cyclosporine.
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
CN101212954A (en) * 2005-05-10 2008-07-02 伊兰制药国际有限公司 Nanoparticle Clopidogrel Formulation
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
EA015336B1 (en) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Nanoparticulate acetaminophen stable formulation
ATE459341T1 (en) * 2005-06-03 2010-03-15 Elan Pharma Int Ltd NANOPARTICLE SHAPED IMATINIB MESYLATE FORMULATIONS
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2009517485A (en) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド Nanoparticulate and controlled release compositions containing cefditoren
ATE446742T1 (en) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd NANOPARTICULAR EBASTIN FORMULATIONS
EA200800041A1 (en) * 2005-06-13 2008-04-28 Элан Фарма Интернэшнл Лтд. COMPOSITIONS WITH NAPPON HEATING NANOPARTICLES CONTAINING THE COMBINATION OF A NECK WARMING AND ASPIRIN
KR20080027340A (en) * 2005-06-14 2008-03-26 백스터 인터내셔널 인코포레이티드 Pharmaceutical Formulations to Minimize Drug-Drug Interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
US8074906B2 (en) * 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
KR20080033383A (en) * 2005-08-12 2008-04-16 아스트라제네카 아베 Way
EP1937217A2 (en) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoparticulate tadalafil formulations
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
KR20090015994A (en) * 2006-05-30 2009-02-12 엘란 파마 인터내셔널 리미티드 Nanoparticulate Posaconazole Formulations
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
US20080181957A1 (en) * 2006-06-23 2008-07-31 Min Wei Increased amorphous stability of poorly water soluble drugs by nanosizing
EP2037888A2 (en) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
KR20090031618A (en) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 Nanoparticulate Modafinil Formulations
PT2049123E (en) 2006-08-03 2013-03-06 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20110020457A1 (en) * 2006-08-14 2011-01-27 Wayne State University Polymer-surfactant nanoparticles for sustained release of compounds
WO2008027571A2 (en) * 2006-08-30 2008-03-06 Liquidia Technologies, Inc. Nanoparticles having functional additives for self and directed assembly and methods of fabricating same
US20090297626A1 (en) * 2006-11-03 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for preparing metal oxides
JP2010510988A (en) 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ Nanoparticle formulation, method for producing the same and use thereof
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
JP2010517759A (en) * 2007-02-09 2010-05-27 アストラゼネカ・アクチエボラーグ Method for producing a stable dispersion of solid amorphous submicron particles in an aqueous medium
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008137960A1 (en) * 2007-05-07 2008-11-13 Questor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN AMINO-FUNCTIONALIZED METHACRYLATE COPOLYMER
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
TWI580441B (en) * 2008-09-19 2017-05-01 愛爾康研究有限公司 Stabilized pharmaceutical sub-micron suspensions and methods of forming same
CA2746887C (en) 2008-12-15 2016-07-05 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
EP2421525B1 (en) 2009-04-24 2017-06-07 Iceutica Pty Ltd. Diclofenac formulation
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
FR2945950A1 (en) 2009-05-27 2010-12-03 Elan Pharma Int Ltd ANTICANCER NANOPARTICLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME
TR200904500A2 (en) 2009-06-10 2009-10-21 Öner Levent Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals.
WO2010146407A1 (en) 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
WO2011118960A2 (en) 2010-03-22 2011-09-29 (주)바이오시네틱스 Method for preparing nano-particles
US10463633B2 (en) 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US9511037B2 (en) 2010-04-23 2016-12-06 Genco Sciences Llc Compositions for reduction of side effects
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
PT3415139T (en) 2011-06-14 2022-06-20 Neurelis Inc Administration of benzodiazepine
KR101794032B1 (en) 2011-09-21 2017-11-07 (주)바이오시네틱스 Method for preparing nanoparticles
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US10471131B2 (en) 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
EP2804606B1 (en) 2012-01-19 2017-06-28 Hybrid Medical, LLC Topical therapeutic formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
EP2964198A2 (en) * 2013-03-04 2016-01-13 vTv Therapeutics LLC Stable glucokinase activator compositions
LT3102185T (en) 2014-02-03 2022-01-10 Apurano Pharmaceuticals Gmbh Nanosuspension of natural materials and preparation method thereof
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
WO2016134121A1 (en) * 2015-02-20 2016-08-25 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
CA2976689C (en) * 2015-03-04 2019-08-06 Kalyanam Nagabhushanam Method to solubilize curcuminoids in water
CN107709344B (en) 2015-05-01 2022-07-15 共晶制药股份有限公司 Nucleoside analogs for the treatment of Flaviviridae and cancer
KR20180082457A (en) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 Injectable neuro-steroid agents containing nanoparticles
BR112019002538A2 (en) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. use of a pharmaceutical composition comprising an allosteric modulator, use of a pharmaceutical composition comprising garboxadol or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for parenteral administration
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN109152745A (en) 2017-04-21 2019-01-04 株式会社生物研究 Using lipid as the method for preparing active material nanoparticle of the lubricant in grinding process
MX2020006864A (en) 2017-12-27 2020-11-11 Univ Emory Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents.
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
US20190240335A1 (en) * 2018-02-07 2019-08-08 Promedon S.A. Biocompatible Hydrogel Compositions
GEP20257802B (en) 2018-06-11 2025-09-25 Otsuka Pharma Co Ltd Delamanid-containing composition
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
KR20220026538A (en) 2019-06-05 2022-03-04 에모리 유니버시티 Peptidomimetics for the treatment of coronavirus and picornavirus infections
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
EP4069202A1 (en) * 2019-12-02 2022-10-12 Merck Patent GmbH Deposition of nanosuspensions of active pharmaceutical ingredients on carriers
JP7780431B2 (en) 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド Ganaxolone for use in the treatment of tuberous sclerosis complex
DK3928772T3 (en) 2020-06-26 2024-08-19 Algiax Pharmaceuticals Gmbh NANOPARTICULAR COMPOSITION
CN112021483B (en) * 2020-09-11 2022-07-15 宁波聚焦生物医药科技股份有限公司 Effervescent gel dry powder preparation and preparation method thereof
EP4486719A1 (en) 2022-03-02 2025-01-08 Horizon Therapeutics Ireland DAC Process of making a crystalline edg-2 receptor antagonist

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0593627A1 (en) 1991-07-05 1994-04-27 The University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5322679A (en) 1992-12-16 1994-06-21 Sterling Winthrop Inc. Iodinated aroyloxy esters
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
FI965094A0 (en) 1994-06-24 1996-12-18 Nanosystems Llc 2,4,6-Triiod-5-substituted aminophthalate esters which are useful as contrast agents in medical diagnostic photography
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5665330A (en) 1995-02-08 1997-09-09 Nano Systems Llc Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5603916A (en) 1995-05-22 1997-02-18 Nano Systems L.L.C. 3 5-bis alkanoyl amino-2 4 6-triiodobenzyl esters
US5668196A (en) 1995-08-10 1997-09-16 Nanosystems Llc 3-amido-triiodophenyl esters as x-ray contrast agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2002525311A (en) 1998-10-01 2002-08-13 エラン ファーマ インターナショナル，リミティド Sustained release nanoparticle composition
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs

Also Published As

Publication number Publication date
JP4460827B2 (en) 2010-05-12
PT1318788E (en) 2008-03-12
US6592903B2 (en) 2003-07-15
DE60131991T2 (en) 2008-12-04
US6375986B1 (en) 2002-04-23
CA2416109C (en) 2009-02-24
US20020110597A1 (en) 2002-08-15
EP1318788B1 (en) 2007-12-19
WO2002024163A1 (en) 2002-03-28
DE60131991D1 (en) 2008-01-31
CY1107305T1 (en) 2012-11-21
ES2298270T3 (en) 2008-05-16
EP1318788A1 (en) 2003-06-18
DK1318788T3 (en) 2008-04-14
JP2004513886A (en) 2004-05-13
ATE381317T1 (en) 2008-01-15
CA2416109A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001295017A1 (en) Solid dose nanoparticulate compositions
AU2274201A (en) Compounds and compositions for delivering active agents
BG66093B1 (en) Controlled release compositions comprising nimesulide
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
WO2000007979A3 (en) Compounds and compositions for delivering active agents
WO2007048219A3 (en) Sustained drug release composition
CY1108532T1 (en) UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
PT1083884E (en) PROCESS FOR THE STABILIZATION OF POLYVINYL-PYRROLIDONE COMPOSITIONS
MY118151A (en) Pharmaceutical formulations containing voriconazole.
MXPA03007857A (en) Compounds and compositions for delivering active agents.
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
EP1024145A3 (en) Novel azalides and methods of making same
MY157790A (en) Trazodone composition for once a day administration
WO2004034975A3 (en) Sustained release profile modification
GB2364641A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
AU2001297844A1 (en) Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
MXPA03002807A (en) Stabilization of solid drug formulations.
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
WO1999061014A3 (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.
BR0206960A (en) Oral pharmaceutical composition and use of a hydroxypropyl methylcellulose phthalate polymer
AP9801350A0 (en) Parasitical formulations.
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins